Investment Analysts’ Weekly Ratings Updates for Vera Therapeutics (VERA)

A number of firms have modified their ratings and price targets on shares of Vera Therapeutics (NASDAQ: VERA) recently:

  • 11/7/2026 – Vera Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
  • 11/6/2026 – Vera Therapeutics was given a new $87.00 price target by Raymond James Financial.
  • 11/6/2026 – Vera Therapeutics had its price target lowered by Guggenheim from $76.00 to $66.00. They now have a “buy” rating on the stock.
  • 11/6/2026 – Vera Therapeutics had its price target lowered by Wedbush from $34.00 to $29.00. They now have a “neutral” rating on the stock.
  • 11/6/2026 – Vera Therapeutics had its price target lowered by HC Wainwright from $90.00 to $75.00. They now have a “buy” rating on the stock.
  • 10/26/2026 – Vera Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial.
  • 10/23/2026 – Vera Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
  • 10/15/2026 – Vera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 10/12/2026 – Vera Therapeutics is now covered by Leerink Partners. They set a “market perform” rating and a $34.00 price target on the stock.

Vera Therapeutics Stock Performance

VERA stock traded down $0.89 during trading hours on Tuesday, reaching $26.08. The stock had a trading volume of 572,378 shares, compared to its average volume of 1,611,393. The stock has a market capitalization of $1.88 billion, a PE ratio of -4.42 and a beta of 1.07. The stock has a 50-day simple moving average of $30.93 and a 200 day simple moving average of $36.15. Vera Therapeutics, Inc. has a fifty-two week low of $25.82 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.91 and a quick ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($1.30) EPS for the quarter, topping the consensus estimate of ($1.62) by $0.32. The business had revenue of $10.28 million for the quarter, compared to the consensus estimate of $3.42 million. Analysts predict that Vera Therapeutics, Inc. will post -6.00 EPS for the current fiscal year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.

Read More

Receive News & Ratings for Vera Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.